Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma.
HCV
NS3 region
NS5A region
aa substitutions
chronic hepatitis C
chronic infection C
core region
hepatocellular carcinoma
phylogenesis
viral variability
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
09
2021
accepted:
09
11
2021
entrez:
15
12
2021
pubmed:
16
12
2021
medline:
16
12
2021
Statut:
epublish
Résumé
The present paper evaluates the genetic variability of HCV in patients with hepatocellular carcinoma (HCC). Amino acid substitutions (aas) in NS3, NS5A and core regions were analyzed in 17 patients with HCC (Cases) and 13 without HCC (Controls), all naïve to DAAs. For the Cases, a sample of neoplastic liver tissue, non-neoplastic liver tissue and a serum sample were collected; for the Controls, a sample of liver tissue was collected. Sanger sequencing of three regions was performed using homemade protocols. Phylogenetic trees showed that there was no difference in the virus populations in the three compartments analyzed for the three HCV regions in patients with HCC. Low variability and no difference between the Cases and Controls were observed in the core and NS5A regions; however, in the NS3 region, a higher variability was observed in the Cases. No difference was observed in the core region between Cases and Controls. In NS3, aa substitutions at positions 103 and 122 were more frequently found in Cases than Controls (in both cases 50% vs 9.1%, p<0.05); moreover, aas in positions 32, 44 (p=0.035 for both), 79 (p=0.008) and 121 (p=0.018) were observed in the Cases and absent in the Controls. Finally, considering the NS5A region, aa substitutions at positions 37 and 54 were more frequently identified in the Cases than the Controls, but without statistical significance. These data may suggest a higher aa variability in patients with HCC than in those without, especially in the NS3 region.
Sections du résumé
BACKGROUND
BACKGROUND
The present paper evaluates the genetic variability of HCV in patients with hepatocellular carcinoma (HCC).
METHODS
METHODS
Amino acid substitutions (aas) in NS3, NS5A and core regions were analyzed in 17 patients with HCC (Cases) and 13 without HCC (Controls), all naïve to DAAs. For the Cases, a sample of neoplastic liver tissue, non-neoplastic liver tissue and a serum sample were collected; for the Controls, a sample of liver tissue was collected. Sanger sequencing of three regions was performed using homemade protocols.
RESULTS
RESULTS
Phylogenetic trees showed that there was no difference in the virus populations in the three compartments analyzed for the three HCV regions in patients with HCC. Low variability and no difference between the Cases and Controls were observed in the core and NS5A regions; however, in the NS3 region, a higher variability was observed in the Cases. No difference was observed in the core region between Cases and Controls. In NS3, aa substitutions at positions 103 and 122 were more frequently found in Cases than Controls (in both cases 50% vs 9.1%, p<0.05); moreover, aas in positions 32, 44 (p=0.035 for both), 79 (p=0.008) and 121 (p=0.018) were observed in the Cases and absent in the Controls. Finally, considering the NS5A region, aa substitutions at positions 37 and 54 were more frequently identified in the Cases than the Controls, but without statistical significance.
CONCLUSION
CONCLUSIONS
These data may suggest a higher aa variability in patients with HCC than in those without, especially in the NS3 region.
Identifiants
pubmed: 34908854
doi: 10.2147/IDR.S337647
pii: 337647
pmc: PMC8665876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5199-5208Informations de copyright
© 2021 Pisaturo et al.
Déclaration de conflit d'intérêts
The authors declare that we have no conflicts of interest related to this work.
Références
J Clin Virol. 2009 Nov;46(3):222-9
pubmed: 19758839
Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9599-604
pubmed: 11481452
Cell Signal. 2004 Dec;16(12):1375-85
pubmed: 15381253
Virology. 1999 May 25;258(1):100-7
pubmed: 10329572
J Hepatol. 2012 Apr;56(4):908-43
pubmed: 22424438
Cancer Detect Prev. 2004;28(6):385-91
pubmed: 15582261
Liver Int. 2019 Oct;39(10):1986-1998
pubmed: 31172639
Oncotarget. 2016 Sep 20;7(38):62706-62714
pubmed: 27486882
Viruses. 2010 Sep;2(9):2108-33
pubmed: 21994721
Sci Rep. 2016 Jun 01;6:27025
pubmed: 27246310
Annu Rev Pathol. 2015;10:345-70
pubmed: 25387053
World J Hepatol. 2012 Dec 27;4(12):342-55
pubmed: 23355912
Infection. 2020 Feb;48(1):7-17
pubmed: 31347138
World J Hepatol. 2017 Dec 28;9(36):1305-1314
pubmed: 29359013
J Hepatol. 2014 Nov;61(1 Suppl):S45-57
pubmed: 25086286
J Virol. 2001 Feb;75(3):1401-7
pubmed: 11152513
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Virology. 2016 Jun;493:136-41
pubmed: 27035616
J Biol Chem. 2008 Oct 24;283(43):29396-404
pubmed: 18728014
Proc Natl Acad Sci U S A. 2016 Feb 2;113(5):1375-80
pubmed: 26787866
Hepatol Res. 2008 Jan;38(1):1-26
pubmed: 17894800
J Hepatol. 2010 Jan;52(1):72-8
pubmed: 19910070
J Transl Med. 2009 Oct 12;7:85
pubmed: 19821982
PLoS One. 2013 Jul 03;8(7):e65336
pubmed: 23843939
Virology. 2002 Jan 20;292(2):272-84
pubmed: 11878930
Mol Carcinog. 2017 Feb;56(2):371-380
pubmed: 27163636
F1000Res. 2016 May 12;5:
pubmed: 27239288
Antivir Ther. 2019;24(7):485-493
pubmed: 30758299
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Gen Virol. 1999 May;80 ( Pt 5):1179-1183
pubmed: 10355764
Cancer Sci. 2009 Dec;100(12):2465-8
pubmed: 20175782
J Med Virol. 2018 Jun;90(6):1087-1093
pubmed: 29427443
World J Gastroenterol. 2014 Jun 21;20(23):7104-22
pubmed: 24966583
J Gen Virol. 2001 Sep;82(Pt 9):2235-2241
pubmed: 11514734